CGChahinda Ghossein-Doha

Chahinda Ghossein-Doha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chahinda Ghossein-Doha has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health-related quality of life of adult post COVID-19 condition patients three years after infection and patient characteristics associated with change over time: a longitudinal analysis from the CORFU study

    by Marcela M. Suazo Guevara, Sophie F. Waardenburg, Dorthe O. Klein, Gouke J. Bonsel, Erwin Birnie, Marieke S. J. N. Wintjens, Bas C. T. van Bussel, Susanne van Santen, Chahinda Ghossein-Doha, Michiel C. Warlé, et al.

    Purpose: Post COVID-19 Condition (PCC) negatively impacts Health Related Quality of Life (HRQoL) and can persist for years after initial infection. This study examined long term HRQoL of COVID-19 survivors with PCC to explore whether and how HRQoL changes over time, and to determine which patient characteristics are associated with changes. Methods: COVID-19 survivors from the Dutch CORona Follow-Up (CORFU) study were prospectively followed for up to 3 years post-infection using self-report questionnaires. PCC was defined on presence of symptoms reported at the 2-year time point. Within-person change in EQ-5D-5L utility and EQ VAS scores were analyzed from the 2-year to the 3-year time point. Changes were described using summary statistics, and associations with patient characteristics were analyzed using multivariable linear regressions. Results: Among 158 participants that met PCC definition 2-years after infection, mean utility and EQ VAS change score was 0.01 (95%CI − 0.02,0.04), and 0.9 (95%CI − 1.6,3.4), respectively. Based on EQ utility change scores, 30% experienced a decrease, 32% an increase, and 37% no change. Similar distributions were observed for EQ VAS. Female sex was associated with decreasing utility scores. Increasing utility scores were associated with female sex of older age when compared to younger ones, and with people that initially reported social participation problems.. Conclusion: Individual changes in HRQoL within a year vary widely in the PCC population. Our findings suggest that certain subgroups of individuals with PCC are more vulnerable to prolonged declines in HRQoL.


  • Female- and age-specific reference values for blood pressure and its relationship with cardiac aberrations after pre-eclampsia

    by Emma B N J Janssen, Robert-Jan Alers, Eva G Mulder, Eri Morina-Shijaku, Maureen J van der Vlugt, Tobias F S Pustjens, Trang H T Dinh, Arnoud W J van ‘t Hof, Marc E A Spaanderman, Chahinda Ghossein-Doha

    Aims: Cardiovascular risk increases progressively increases from lower blood pressure (BP) values in females than males, questioning current universal thresholds for hypertension. In this study, we established female- and age-specific thresholds for hypertension and assessed its association with subclinical cardiac aberrations in a high-risk female group of women after pre-eclampsia. Methods: A standardized cross-sectional cardiovascular assessment was performed among former pregnant women, including 30-minutes BP measurement and transthoracic echocardiography to assess cardiac function and remodelling. Women with a history of normotensive pregnancy constituted the cardiovascular healthy reference group, in whom we established thresholds for elevated BP (≥95th percentile). The risk for subclinical cardiac aberrations in case of elevated BP was evaluated among former pre-eclamptic women. Results: A number of 463 women were included in the healthy reference group and 951 formerly pre-eclamptic women (43 ± 8 and 39 ± 8 years, respectively). Female-specific thresholds defining hypertension were 132.8 mmHg systolic or 81.0 mmHg diastolic. Among former pre-eclamptic women, systolic BP levels above ≥132.8 mmHg but below current diagnostic threshold for hypertension (<140 mmHg) significantly associated with increased odds for left ventricular concentric remodelling [OR = 2.1, 95% confidence interval (CI) 1.1–4.2], diastolic dysfunction [OR = 4.5 (1.4–14.2)], and subclinical heart failure (OR = 2.3, 95% CI 1.2–4.2). Conclusion: For relatively young women, female-specific thresholds for hypertension are lower than ESC/ESH guidelines (≥133/81 vs. ≥140/90 mmHg), and associate with cardiac dysfunction in formerly pre-eclamptic women. Sex- and age-tailored interpretation of BP improves prevention of heart failure development and progression among high-risk women.


  • Open Access

    A call to action on pregnancy-related lifestyle interventions to reduce cardiovascular risk in the offspring: a scientific statement of the European Association of Preventive Cardiology of the European Society of Cardiology

    by Trine Moholdt, Christina Aye, Martin Bahls, Fatima Crispi, Chahinda Ghossein-Doha, Eva Goossens, Henner Hanssen, Aparna Kulkarni, Adam J Lewandowski, Dominique Mannaerts, et al.

    Adverse pregnancy outcomes, such as gestational diabetes, hypertensive disorders of pregnancy, fetal growth restriction, and prematurity, can increase the risk of future cardiovascular disease (CVD) in the offspring. This document aims to raise recognition of the impact of maternal health on offspring cardiometabolic health and to highlight research gaps on how to mitigate this risk via pregnancy-related lifestyle interventions. Lifestyle interventions initiated before, during, or after pregnancy hold great promise to prevent and manage adverse maternal outcomes. Still, there is limited evidence for the effect of such interventions on CVD-related outcomes in the offspring. In this document, we ‘call for action’ concerning research investigating how pregnancy-related lifestyle interventions can reduce CVD risk in the offspring. There is a need to overcome barriers to recruit individuals who need such interventions the most, to better design strategies for increased adherence, and to include relevant measurements in children.


  • Open Access

    Sex Differences in the Anti-Hypertensive Effect of Calcium-Channel Blockers: A Systematic Review and Meta-Analysis

    by Eveline M. van Luik, Esmée W. P. Vaes, Maud A. M. Vesseur, Nick Wilmes, Daniek A. M. Meijs, Sophie A. J. S. Laven, Zenab Mohseni-Alsalhi, Sander de Haas, Marc E. A. Spaanderman, Chahinda Ghossein-Doha

    Cardiovascular disease (CVD) is the number one cause of death worldwide, with hypertension as the leading risk factor for both sexes. As sex may affect responsiveness to antihypertensive compounds, guidelines for CVD prevention might necessitate divergence between females and males. To this end, we studied the effectiveness of calcium channel blockers (CCB) on blood pressure (BP), heart rate (HR) and cardiac function between sexes. We performed a systematic review and meta-analysis on studies on CCB from inception to May 2020. Studies had to present both baseline and follow-up measurements of the outcome variables of interest and present data in a sex-stratified manner. Mean differences were calculated using a random-effects model. In total, 38 studies with 8202 participants were used for this review. In females as compared to males, systolic BP decreased by −27.6 mmHg (95%CI −36.4; −18.8) (−17.1% (95%CI −22.5;−11.6)) versus −14.4 mmHg (95%CI −19.0; −9.9) (−9.8% (95%CI −12.9;−6.7)) (between-sex difference p < 0.01), diastolic BP decreased by −14.1 (95%CI −18.8; −9.3) (−15.2%(95%CI −20.3;−10.1)) versus −10.6 mmHg (95%CI −14.0; −7.3) (−11.2% (95%CI −14.8;−7.7)) (between-sex difference p = 0.24). HR decreased by −1.8 bpm (95%CI −2.5; −1.2) (−2.5% (95%CI −3.4; −1.6)) in females compared to no change in males (0.3 bpm (95% CI −1.2; 1.8)) (between-sex difference p = 0.01). In conclusion, CCB lowers BP in both sexes, but the observed effect is larger in females as compared to males.


  • Open Access

    Exploring Sex Differences of Beta-Blockers in the Treatment of Hypertension: A Systematic Review and Meta-Analysis

    by Nick Wilmes, Eveline M. van Luik, Esmée W. P. Vaes, Maud A. M. Vesseur, Sophie A. J. S. Laven, Zenab Mohseni-Alsalhi, Daniek A. M. Meijs, Cédric J. R. Dikovec, Sander de Haas, Marc E. A. Spaanderman, et al.

    Aims: In the prevention of cardiovascular morbidity and mortality, early recognition and adequate treatment of hypertension are of leading importance. However, the efficacy of antihypertensives may be depending on sex disparities. Our objective was to evaluate and quantify the sex-diverse effects of beta-blockers (BB) on hypertension and cardiac function. We focussed on comparing hypertensive female versus male individuals. Methods and results: A systematic search was performed for studies on BBs from inception to May 2020. A total of 66 studies were included that contained baseline and follow up measurements on blood pressure (BP), heart rate (HR), and cardiac function. Data also had to be stratified for sex. Mean differences were calculated using a random-effects model. In females as compared to males, BB treatment decreased systolic BP 11.1 mmHg (95% CI, −14.5; −7.8) vs. 11.1 mmHg (95% CI, −14.0; −8.2), diastolic BP 8.0 mmHg (95% CI, −10.6; −5.3) vs. 8.0 mmHg (95% CI, −10.1; −6.0), and HR 10.8 beats per minute (bpm) (95% CI, −17.4; −4.2) vs. 9.8 bpm (95% CI, −11.1; −8.4)), respectively, in both sexes’ absolute and relative changes comparably. Left ventricular ejection fraction increased only in males (3.7% (95% CI, 0.6; 6.9)). Changes in left ventricular mass and cardiac output (CO) were only reported in males and changed −20.6 g (95% CI, −56.3; 15.1) and −0.1 L (95% CI, −0.5; 0.2), respectively. Conclusions: BBs comparably lowered BP and HR in both sexes. The lack of change in CO in males suggests that the reduction in BP is primarily due to a decrease in vascular resistance. Furthermore, females were underrepresented compared to males. We recommend that future research should include more females and sex-stratified data when researching the treatment effects of antihypertensives.


  • Open Access

    The Representation of Females in Studies on Antihypertensive Medication over the Years: A Scoping Review

    by Zenab Mohseni-Alsalhi, Maud A. M. Vesseur, Nick Wilmes, Sophie A. J. S. Laven, Daniek A. M. Meijs, Eveline M. van Luik, Esmée W. P. Vaes, Cédric J. R. Dikovec, Jan Wiesenberg, Mohamad F. Almutairi, et al.

    Background: The leading global risk factor for cardiovascular-disease-related morbidity and mortality is hypertension. In the past decade, attention has been paid to increase females’ representation. The aim of this study is to investigate whether the representation of females and presentation of sex-stratified data in studies investigating the effect of antihypertensive drugs has increased over the past decades. Methods: After systematically searching PubMed and Embase for studies evaluating the effect of the five major antihypertensive medication groups until May 2020, a scoping review was performed. The primary outcome was the proportion of included females. The secondary outcome was whether sex stratification was performed. Results: The search resulted in 73,867 articles. After the selection progress, 2046 studies were included for further analysis. These studies included 1,348,172 adults with a mean percentage of females participating of 38.1%. Female participation in antihypertensive studies showed an increase each year by 0.2% (95% CI 0.36–0.52), p < 0.01). Only 75 (3.7%) studies performed sex stratification, and this was the highest between 2011 and 2020 (7.2%). Conclusion: Female participation showed a slight increase in the past decade but is still underrepresented compared to males. As data are infrequently sex-stratified, more attention is needed to possible sex-related differences in treatment effects to different antihypertensive compounds.


  • Open Access

    Editorial: Hypertensive disorders of pregnancy and the cardiovascular system: Causes, consequences, prevention and treatment

    by Inge Dierickx, Robert-Jan Alers, Rossana Orabona, Edoardo Sciatti, Marc Spaanderman, Federico Prefumo, Chahinda Ghossein-Doha

    Editorial: Hypertensive disorders of pregnancy and the cardiovascular system: Causes, consequences, prevention and treatment

  • Open Access

    Vascular Function, Systemic Inflammation, and Coagulation Activation 18 Months after COVID-19 Infection: An Observational Cohort Study

    by Loes H. Willems, Lotte M. C. Jacobs, Laszlo A. Groh, Hugo Ten Cate, Henri M. H. Spronk, Boden Wilson-Storey, Gerjon Hannink, Sander M. J. van Kuijk, Chahinda Ghossein-Doha, Magdi Nagy, et al.

    Introduction: Among its effect on virtually all other organs, COVID-19 affects the cardiovascular system, potentially jeopardizing the cardiovascular health of millions. Previous research has shown no indication of macrovascular dysfunction as reflected by carotid artery reactivity, but has shown sustained microvascular dysfunction, systemic inflammation, and coagulation activation at 3 months after acute COVID-19. The long-term effects of COVID-19 on vascular function remain unknown. Materials and Methods: This cohort study involved 167 patients who participated in the COVAS trial. At 3 months and 18 months after acute COVID-19, macrovascular dysfunction was evaluated by measuring the carotid artery diameter in response to cold pressor testing. Additionally, plasma endothelin-1, von Willebrand factor, Interleukin(IL)-1ra, IL-6, IL-18, and coagulation factor complexes were measured using ELISA techniques. Results: The prevalence of macrovascular dysfunction did not differ between 3 months (14.5%) and 18 months (11.7%) after COVID-19 infection (p = 0.585). However, there was a significant decrease in absolute carotid artery diameter change, 3.5% ± 4.7 vs. 2.7% ± 2.5, p—0.001, respectively. Additionally, levels of vWF:Ag were persistently high in 80% of COVID-19 survivors, reflecting endothelial cell damage and possibly attenuated endothelial function. Furthermore, while levels of the inflammatory cytokines interleukin(IL)-1RA and IL-18 were normalized and evidence of contact pathway activation was no longer present, the concentrations of IL-6 and thrombin:antithrombin complexes were further increased at 18 months versus 3 months (2.5 pg/mL ± 2.6 vs. 4.0 pg/mL ± 4.6, p = 0.006 and 4.9 μg/L ± 4.4 vs. 18.2 μg/L ± 11.4, p < 0.001, respectively). Discussion: This study shows that 18 months after COVID-19 infection, the incidence of macrovascular dysfunction as defined by a constrictive response during carotid artery reactivity testing is not increased. Nonetheless, plasma biomarkers indicate sustained endothelial cell activation (vWF), systemic inflammation (IL-6), and extrinsic/common pathway coagulation activation (FVII:AT, TAT) 18 months after COVID-19 infection.


  • Open Access

    The underrepresentation of females in antihypertensive medication over the years: a scoping review

    by Z Mohseni-Alsalhi, M A M Vesseur, S A J S Laven, E W P Vaes, N Wilmes, D A M Meijs, E M Van Luik, C J R Dikovec, J Wiesenberg, M F Almutairi, et al.

    Background: Hypertension is one of the leading global risk factors for cardiovascular disease-related morbidity and mortality. Females have historically been underrepresented in clinical trials resulting in presumed sex-related disparities in antihypertensive treatment effects. The past decade, widespread attention has been paid to this shortcoming aiming at increasing females' representation in clinical trials. Purpose: To investigate whether in studies investigating the effect of antihypertensive drugs 1) the representation of females and 2) presentation of sex-stratified data has increased over the past decades. Methods: We performed a scoping review after systematically searching PubMed and Embase for studies evaluating the effects of the five major groups of antihypertensive medication from inception (1945) until May 2020. The review was registered in Prospero database. Studies were only included if they 1) investigated one class of the five main groups of antihypertensive medications (beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, and diuretics, 2) human studies, 3) investigated adults ≥18 years of age, 4) were written in English or Dutch. We excluded articles if 1) only abstract was available and full report was not found, 2) unsuitable study design, 3) no reference group included, 4) outcome not related to cardiovascular health, 5) no registration of specific dose and duration information. The primary outcome was the proportion of included females over time, stratified per decade. The secondary outcome was whether sex-stratification was reported. Linear regression analysis with beta coefficient (β) and 95% CI was performed to explore the associations between the percentage of females included in the studies over time. Results: The search strategy resulted in 73,867 potential articles. After study selection based on title/abstract and full text, 2,079 original studies were eligible for our study. These included 1,395,264 adults of which the mean percentage of females participating in all included studies was 27.9% (Figure 1, Table 1). The percentage of females participating in antihypertensive studies showed a slight increase each year by 0.4% (95% CI 0.36–0.53, P<0.01). The yearly increase was the highest between 2001 and 2010 being 0.52% (95% CI 0.076–0.954) and in the most recent decade (between 2011 and 2020) 38.7% of included participants were female. Sex-stratification was performed in 76 (3.7%) studies and was the highest between 2011 and 2020 (7.3%). Conclusion: Despite yearly increase in female participation in antihypertensive studies, females still only account for only one third of the study population. Moreover, less than 10% of studies report sex stratified data. Considering the global burden of hypertension, more differentiated sex-specific attention remains critically needed. Funding Acknowledgement: Type of funding sources: None.

  • Open Access

    A prediction model for aberrant cardiac remodelling in women after preeclampsia; Queen of Hearts study

    by Z Mohseni-Alsalhi, E B N J Janssen, J Delmarque, S M J Van Kuijk, M E A Spaanderman, C Ghossein-Doha

    Background: Preeclampsia, a hypertensive pregnancy disorder, is strongly associated with aberrant left ventricular remodelling up to ten years after delivery and heart failure later in life. To detect occult cardiac abnormalities, echocardiography is necessary but not feasible for all these women. A prediction model for aberrant cardiac remodelling to be used in primary care may guide towards intensified follow-up for those at risk or tempered follow-up for low-risk individuals. Purpose: To develop a prediction model for aberrant left ventricular remodelling in former pregnant women weighing their complicated pregnancy. Methods: In this large cohort study, we included women (aged ≥18 years) with a history of preeclampsia or normotensive pregnancy at a postpartum interval of 6 months until 30 years. Comprehensive cardiovascular assessment was performed, including echocardiography, 30-minutes blood pressure measurements and circulating biomarkers. The procedures were in accordance with institutional guidelines and adhered to the principles of the Declaration of Helsinki. Aberrant cardiac remodelling based on echocardiography was defined as either left ventricular concentric remodelling or left ventricular hypertrophy. A prediction model based on clinical and circulating markers was developed using univariable and multivariable logistic regression with backward elimination. Internal validation was performed using Heuristic shrinkage factor. Performance of the final model was evaluated in terms of discrimination by the area under the receiver operating characteristic (AUC-ROC) curve. Results: We included 1466 women, of which 93 (6.3%) with left ventricular concentric remodelling and/or left ventricular hypertrophy (mean ± SD age, 43±10 years) and 1373 (93.7%) without left ventricular concentric remodelling and/or left ventricular hypertrophy (40±8 years). The final prediction model was based on the predictors age, waist circumference, systolic blood pressure, Homeostatic Model Assessment of Insulin Resistance (HOMAIR), and preeclampsia (y/n) (Table 1). After internal validation, this prediction model showed a good discriminative ability of AUC-ROC-curve 0.71 (95% CI 0.661–0.758) (Figure 1). Conclusion: We developed a good-performing prediction model for aberrant cardiac remodelling in former pregnant women based on five conventional variables that could contribute to risk-guided follow-up after preeclampsia aiming at intensifying follow-up for those at risk and tempered follow-up for low-risk women. Funding Acknowledgement: Type of funding sources: None.